Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2010
08/24/2010CA2423103C N-acylsulfonamide apoptosis promoters
08/24/2010CA2377560C Incorporation and applications of biomolecular interactions within a carrier
08/24/2010CA2356189C Substance for obtaining highly effective tumor medications as well as a process
08/24/2010CA2302226C Camptothecin analogs and methods of preparation thereof
08/24/2010CA2273821C Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease
08/24/2010CA2213560C Pharmaceutical compositions for controlled release of soluble receptors
08/19/2010WO2010094009A2 Methods and compositions for the treatment of ras associated disorders
08/19/2010WO2010093789A2 Combinational compositions and methods for treatment of cancer
08/19/2010WO2010093655A2 Enhanced method for producing stem-like cells from somatic cells
08/19/2010WO2010093627A2 Fibronectin type iii domain based scaffold compositions, methods and uses
08/19/2010WO2010093615A2 Compounds, their syntheses, compositions, and methods to treat cancer
08/19/2010WO2010093605A1 Isotopologues of thalidomide
08/19/2010WO2010093435A1 Methods for treating non-small cell lung cancer using 5-azacytidine
08/19/2010WO2010093434A1 Isotopologues of lenalidomide
08/19/2010WO2010093420A2 Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof
08/19/2010WO2010093419A1 Novel amino azaheterocyclic carboxamides
08/19/2010WO2010093324A1 Use of antisecretory factors (af) for optimizing cellular uptake
08/19/2010WO2010093263A1 Compositions and methods for the treatment and prevention of neoplastic disorders
08/19/2010WO2010093055A1 Anti-mst1r antibodies and uses thereof
08/19/2010WO2010092974A1 Brain tumor stem cell differentiation promoter, and therapeutic agent for brain tumor
08/19/2010WO2010092962A1 Hetero ring derivative
08/19/2010WO2010092660A1 Inhibitor of casein kinase 1δ and casein kinase 1ε
08/19/2010WO2010092546A1 Androgen receptor modulating compounds, preparation and uses thereof
08/19/2010WO2010092489A1 Derivatives of azaindoles as inhibitors of protein kinases abl and src
08/19/2010WO2010092371A1 Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
08/19/2010WO2010092260A2 Pharmaceutical compositions of 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate
08/19/2010WO2010092079A1 C-cbl and antagonists thereof for the treatment and diagnosis of cancer
08/19/2010WO2010092015A1 Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
08/19/2010WO2010091979A1 Spiroindolinone pyridine derivative
08/19/2010WO2010091824A1 Fused pyrimidines as akt inhibitors
08/19/2010WO2010091808A1 Fused pyrimidines
08/19/2010WO2010091650A1 Polymeric conjugates of paclitaxel and docetaxel with ph-controlled releasing of the cancerostatic agent
08/19/2010WO2010091629A1 Chemical complexing directional separation and purification method for preparing high-purity beta-elemene raw material medicament
08/19/2010WO2010091543A1 Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists
08/19/2010WO2010091542A1 Anti-tumor, anti-bacterial and/or anti-viral applications of ctla4ig and derivatives thereof.
08/19/2010WO2010075280A3 Coumarin-based compounds for the treatment of alzheimer's disease and cancer
08/19/2010WO2010075255A3 Methods for treating or preventing cancer and neurodegenerative diseases
08/19/2010WO2010073126A3 Compounds useful in delivering anti-neoplastic therapy and diagnostic imaging to hypoxic cells and methods of use thereof
08/19/2010WO2010072734A3 Targeting prodrugs and compositions for the treatment of gastrointestinal diseases
08/19/2010WO2010066803A3 Human antibodies against human tissue factor
08/19/2010WO2010065116A9 The use of il-27-p28 to antagonize il-6 mediated signaling
08/19/2010WO2010062144A3 Ethacrynic acid-containing composition and method for prevention and treatment of transglutaminase-related diseases
08/19/2010WO2010056985A9 Treatment of proteinopathies using a farnesyl transferase inhibitor
08/19/2010WO2010054397A3 N-cadherin: target for cancer diagnosis and therapy
08/19/2010WO2010054381A3 Method of treating cancer with a combination of a proteasome inhibitor and salubrinal
08/19/2010WO2010051533A3 Compositions of engineered human arginases and methods for treating cancer
08/19/2010WO2010048623A8 Medical and imaging nanoclusters
08/19/2010WO2010048530A3 Methods and compositions employing an iip45 targeting ligand
08/19/2010WO2010045542A3 Fused ring heteroaryl kinase inhibitors
08/19/2010WO2010045281A3 Stable aqueous formulations of water insoluble or poorly soluble drugs
08/19/2010WO2010042636A3 Telomerase inhibitors and methods of use thereof
08/19/2010WO2010042500A3 Heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
08/19/2010WO2010039798A3 Amorphous compositions of sunitinib base and l-malic acid
08/19/2010WO2010033862A3 Methods for treating cancer using npar agonists
08/19/2010WO2010033249A3 Compositions of and methods of using ligand dimers
08/19/2010WO2010032248A3 Multifunctional albumin conjugates
08/19/2010WO2010031825A3 Methods and compositions for the treatment of cancer
08/19/2010WO2010026596A3 Compositions comprising polyhydroxyltate fatty alcohol derivatives and the therapeutic uses
08/19/2010WO2009122034A8 Novel hsp90 inhibitory carbazole derivatives, compositions containing same, and use thereof
08/19/2010US20100212037 Mia-2 protein
08/19/2010US20100212033 Novel ubiquitin lifases as therapeutic tragets
08/19/2010US20100210838 Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity
08/19/2010US20100210818 Nucleic acids encoding the human alex1 protein
08/19/2010US20100210738 Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
08/19/2010US20100210735 Modulating the Activity of Nuclear Receptors in Order to Treat Hypoxia-Related Disorders
08/19/2010US20100210733 Composition for Prevention or Treatment of Bone Metabolism Disorder Comprising D-Pinitol as an Active Ingredient
08/19/2010US20100210729 Methods of inducing terminal differentiation
08/19/2010US20100210727 Hepoxilin analog enantiomers
08/19/2010US20100210714 Her-2/neu DNA Vaccine Having Anti-Cancer Activity
08/19/2010US20100210710 THERAPEUTIC siRNA MOLECULES FOR REDUCING VEGFR1 EXPRESSION IN VITRO AND IN VIVO
08/19/2010US20100210707 Small Activating RNA Molecules and Methods of Use
08/19/2010US20100210701 Novel Forms of Bendamustine Free Base
08/19/2010US20100210700 Methods of treatment using intravenous formulations comprising temozolomide
08/19/2010US20100210699 Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
08/19/2010US20100210694 New no-donor aspirin derivatives
08/19/2010US20100210692 Methods of treatment using sirt modulators and compositions containing sirt1 modulators
08/19/2010US20100210681 Aqueous pharmaceutical composition
08/19/2010US20100210678 Tricyclic androgen receptor modulator compounds and methods
08/19/2010US20100210677 Novel compound, corresponding compositions, preparation and/or treatment methods
08/19/2010US20100210674 Spiroindolinone Derivatives
08/19/2010US20100210673 Pyrimidylaminobenzamide derivatives for systemic mastocytosis
08/19/2010US20100210671 Quinazolinone T-Type Calcium Channel Antagonists
08/19/2010US20100210670 Methods and compostions utiliziing quinazolinones
08/19/2010US20100210666 Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy
08/19/2010US20100210665 Diarylhydantoin compounds
08/19/2010US20100210660 Heterocyclic FXR Binding Compounds
08/19/2010US20100210658 Novel tetracyclic heteroatom containing derivatives useful as sex steroid hormone receptor modulators
08/19/2010US20100210650 Isoxazole compound for the treatment of cancer
08/19/2010US20100210649 Pyridazinones and furan-containing compounds
08/19/2010US20100210648 Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
08/19/2010US20100210646 2-morpholin-4-yl-pyrimidines as pi3k inhibitors
08/19/2010US20100210644 Chemical compounds
08/19/2010US20100210641 Organic Compounds
08/19/2010US20100210639 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h 1,3,6,9 tetraaza-fluorenes as chk1 kinase function inhibitors
08/19/2010US20100210636 Benzoxazinone derivative
08/19/2010US20100210635 Renin inhibitors
08/19/2010US20100210627 Pyrazine compounds, their use and methods of preparation
08/19/2010US20100210623 Therapeutic compounds
08/19/2010US20100210622 Heterocyclic compounds and methods of use
08/19/2010US20100210620 Substituted Aryl Sulfone Derivatives as Calcium Channel Blockers
1 ... 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 ... 2211